Corrects company name in headline
** Shares of Argenica Therapeutics AGN.AX rise 3.1% to A$0.675, their highest level since Jan. 21
** Clinical drug developer announces that the Data Safety Monitoring Board recommends that trials for its drug ARG-007, continue without any changes
** ARG-007 is a drug to reduce the death of brain tissue after a stroke
** 132,174 shares change hands, 1.4 times the 30-day average
** Stock up 7.9% this month, including session's moves
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。